Bortezomib – Uses, Dosage, Side Effects, Interaction Bortezomib is a proteasome inhibitor and antineoplastic agent that is used in the treatment of refractory multiple myeloma and certain lymphomas. Bortezomib is associated with a low rate of serum enzyme elevations during treatment and with rare instances of clinically apparent, acute liver injury. Bortezomib is l-Phenylalaninamide substituted at the amide nitrogen by a 1-(dihydroxyboranyl)-3-methyl butyl group and at N(alpha) by a pyrazin-2-ylcarbonyl group. It is a dipeptidyl boronic acid that reversibly inhibits the 26S proteasome. It has a role as an antineoplastic agent, a proteasome inhibitor, a protease inhibitor, and an antiprotozoal drug. It is an amino acid amide, a member of pyrazines, and an L-phenylalanine derivative. It is functionally related to boronic acid. Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib. Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic lupus erythematosus, rheumatoid arthritis, and solid tumors. Mechanism of Action The ubiquitin-proteasome pathway is a homeostatic proteolytic pathway for intracellular protein degradation: proteins marked with a poly-ubiquitin chain are degraded to small peptides and free ubiquitin by the proteasome, which is a large multimeric protease. Aberrant proteasome-dependent proteolysis, as seen in some malignancies, can lead to uncontrolled cell division, leading to tumorigenesis, cancer growth, and spread. Bortezomib is a reversible inhibitor of the 26S proteasome, which is made up of a 20S core complex with a 19S regulatory complex. Individual β-subunits allow specific catalytic action of the 20S core. In mammalian cells, bortezomib is a potent inhibitor of the proteasome’s chymotryptic-like activity, which is attributed to the β5-subunit of the 20S core particle. Bortezomib binds to the active site of the threonine hydroxyl group in the β5-subunit. A probing study showed bortezomib also binding to and inhibiting the β1-subunit, which mediates the caspase-like activity of the proteasome, and the β1i-subunit, which is an altered subunit that is expressed to form immunoproteasomes in response to cell stress or inflammation. By inhibiting the proteasome-mediated degradation of key proteins that promote cell apoptosis, bortezomib induces a cell cycle arrest during the G2-M phase. It is believed that multiple mechanisms, other than proteasome inhibition, may be involved in the anticancer activity of bortezomib. The anticancer activity of bortezomib was largely associated with the suppression of the NF-κB signaling pathway, resulting in the downregulation of anti-apoptotic target genes and expression of anti-apoptotic proteins. This may be explained by bortezomib preventing uncontrolled degradation of IκB, which is an inhibitory protein of NF-κB. NOXA, which is a pro-apoptotic factor, is induced by bortezomib selectively in cancer cells; thus, it is suggested to be another key mechanism of bortezomib. or Bortezomib, a modified dipeptidyl boronic acid, is an antineoplastic agent. The drug reversibly inhibits the 26S proteasome, a large protein complex that degrades ubiquitinated proteins. The ubiquitin-proteasome pathway plays an essential role in regulating the intracellular concentration of specific proteins, thereby maintaining homeostasis within cells. Inhibition of the 26S proteasome by bortezomib prevents targeted proteolysis and causes disruption of normal homeostatic mechanisms, which can lead to cell death. In vitro studies indicate that bortezomib is cytotoxic to a variety of cancer cell types. Bortezomib has been shown to cause a delay in tumor growth in vivo in tumor models, including multiple myeloma. Indications Bortezomib is indicated for the treatment of adult patients with multiple myeloma or mantle cell lymphoma. Velcade as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for hematopoietic stem cell transplantation. Velcade in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with hematopoietic stem cell transplantation. Velcade in combination with dexamethasone, or with dexamethasone and thalidomide, is indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with hematopoietic stem cell transplantation. Velcade in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for hematopoietic stem cell transplantation. Bortezomib Hospira as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for hematopoietic stem cell transplantation. Bortezomib Hospira in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with hematopoietic stem cell transplantation. Bortezomib Hospira in combination with dexamethasone, or with dexamethasone and thalidomide, is indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with hematopoietic stem cell transplantation. Bortezomib Hospira in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for hematopoietic stem cell transplantation. Bortezomib as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for hematopoietic stem cell transplantation. Bortezomib in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with hematopoietic stem cell transplantation. Bortezomib in combination with dexamethasone, or with dexamethasone and thalidomide, is indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with hematopoietic stem cell transplantation. Bortezomib in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for hematopoietic stem cell transplantation. Bortezomib SUN as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for hematopoietic stem cell transplantation. Bortezomib SUN in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with hematopoietic stem cell transplantation. Bortezomib SUN in combination with dexamethasone, or with dexamethasone and thalidomide, is indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high-dose chemotherapy with hematopoietic stem cell transplantation. Bortezomib SUN in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for hematopoietic stem cell transplantation. Bortezomib Accord as monotherapy or in combination with pegylated liposomal doxorubicin or dexamethasone is indicated for the treatment of adult patients with progressive multiple myeloma who have received at least 1 prior therapy and who have already undergone or are unsuitable for hematopoietic stem cell transplantation. Bortezomib Accord in combination with melphalan and prednisone is indicated for the treatment of adult patients with previously untreated multiple myeloma who are not eligible for high‑dose chemotherapy with hematopoietic stem cell transplantation. Bortezomib Accord in combination with dexamethasone, or with dexamethasone and thalidomide, is indicated for the induction treatment of adult patients with previously untreated multiple myeloma who are eligible for high‑dose chemotherapy with hematopoietic stem cell transplantation. Bortezomib Accord in combination with rituximab, cyclophosphamide, doxorubicin and prednisone is indicated for the treatment of adult patients with previously untreated mantle cell lymphoma who are unsuitable for hematopoietic stem cell transplantation. Treatment of mantle cell lymphoma Use in Cancer Bortezomib is approved to treat adults with: Mantle cell lymphoma in patients who have received at least one other type of treatment. Multiple myeloma. Bortezomib is also being studied in the treatment of other types of cancer. Contraindications diabetes dehydration decreased blood platelets low levels of a type of white blood cell called neutrophils a painful condition that affects the nerves in the legs and arms called peripheral neuropathy pulmonary hypertension chronic heart failure thrombotic thrombocytopenic purpura, a type of blood disorder orthostatic hypotension, a form of low blood pressure low blood pressure pneumonia a type of inflammation of the lung called interstitial pneumonitis acute respiratory distress syndrome, a type of lung disorder blocked bowels with decreased peristaltic movement liver problems abnormal liver function tests pregnancy a patient who is producing milk and breastfeeding a type of brain disorder called posterior reversible encephalopathy syndrome Child-Pugh class B liver impairment Child-Pugh class C liver impairment Dosage Strengths: 3.5 mg; 2.5 mg; 1 mg; 1 mg/mL; 2.5 mg/mL Lymphoma DOSAGE IN PREVIOUSLY UNTREATED MANTLE CELL LYMPHOMA: 1.3 mg/m2 as a bolus IV injection twice weekly in combination with IV rituximab, cyclophosphamide, doxorubicin, and oral prednisone for two weeks (days 1, 4, 8, and 11) followed by a ten-day rest period (days 12 through 21) The three-week period is considered a treatment cycle. A minimum of 72 hours should elapse between consecutive doses of bortezomib. For patients with a response first documented at cycle 6, two additional cycles (for a total of 8 cycles) are recommended. FOR USE IN THE TREATMENT OF RELAPSED MANTLE CELL LYMPHOMA: Usual dose: 1.3 mg/m2 as a bolus IV injection or subcutaneously twice weekly for two weeks (days 1, 4, 8, and 11) followed by a ten-day rest period (days 12 through 21). Therapy extending beyond 8 cycles may be administered by the standard schedule or may be given once weekly for 4 weeks (days 1, 8, 15, and 22), followed by a 13-day rest (days 23 through 35) Multiple Myeloma FOR USE IN THE TREATMENT OF PREVIOUSLY UNTREATED MULTIPLE MYELOMA: Usual dose: 1.3 mg/m2 administered as a 3 to 5-second bolus IV injection or subcutaneously in combination with oral melphalan and oral prednisone for nine 6-week treatment cycles: In cycles 1 through 4, bortezomib is administered twice weekly (days 1, 4, 8, 11, 22, 25, 29, and 32). In cycles 5 through 9, bortezomib is administered once weekly (days 1, 8, 22, and 29). At least 72 hours should elapse between consecutive doses of bortezomib. FOR USE IN THE TREATMENT OF RELAPSED MULTIPLE MYELOMA: Usual dose: 1.3 mg/m2 as a bolus intravenous injection or subcutaneously twice weekly for two weeks (days 1, 4, 8, and 11) followed by a ten-day rest period (days 12 through 21). Therapy extending beyond 8 cycles may be administered by the standard schedule or may be given once weekly for 4 weeks (days 1, 8, 15, and 22), followed by a 13-day rest (days 23 through 35). Bortezomib may be administered alone or in combination with dexamethasone. The three-week period is considered a treatment cycle. A minimum of 72 hours should elapse between consecutive doses of bortezomib. Patients with multiple myeloma who have previously responded to treatment with bortezomib (either alone or in combination) and who have relapsed at least 6 months after their prior therapy may be started on the last tolerated dose. Moderate to severe hepatic impairment (bilirubin levels greater than 1.5 times the upper limit of normal range [ULN]): Starting doses should be reduced to 0.7 mg/m2 in the first cycle. Dose escalation to 1 mg/m2 or further dose reduction to 0.5 mg/m2 may be considered in subsequent cycles based on patient tolerability. Dose Adjustments DOSE MODIFICATION GUIDELINES FOR COMBINATION THERAPY WITH BORTEZOMIB, MELPHALAN AND PREDNISONE: Prior to initiating any cycle of therapy with bortezomib in combination with melphalan and prednisone: The platelet count should be greater than or equal to 70 x 10^9/L and the ANC should be greater than or equal to 1.0 x 10^9/L. Non-hematological toxicities should have resolved to grade 1 or baseline. Hematological toxicity during a cycle: If prolonged grade 4 neutropenia, thrombocytopenia, or thrombocytopenia with bleeding is observed in the previous cycle, then a reduction of the melphalan dose by 25% in the next cycle should be considered. If the platelet count is less than or equal to 30 x 10^9/L or ANC less than or equal to 0.75 x 10^9/L on a bortezomib dosing day (other than day 1), then the bortezomib dose should be withheld. If several bortezomib doses in consecutive cycles are withheld due to toxicity, the bortezomib dose should be reduced by 1 dose level (from 1.3 mg/m2 to 1 mg/m2, or from 1 mg/m2 to 0.7 mg/m2) Nonhematological toxicities greater than or equal to grade 3: Bortezomib therapy should be withheld until symptoms of the toxicity have resolved to grade 1 or baseline. Then, bortezomib may be reinitiated with one dose level reduction (from 1.3 mg/m2 to 1 mg/m2, or from 1 mg/m2 to 0.7 mg/m2). DOSE MODIFICATION GUIDELINES FOR BORTEZOMIB WHEN GIVEN IN COMBINATION WITH RITUXIMAB, CYCLOPHOSPHAMIDE, DOXORUBICIN, AND PREDNISONE: Prior to the first day of each cycle (other than Cycle 1) of therapy with bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone: Platelet count should be at least 100 x 10^9/L and absolute neutrophil count (ANC) should be at least 1.5 x 10^9/L Hemoglobin should be at least 8 g/dL (at least 4.96 mmol/L) Non-hematologic toxicity should have recovered to Grade 1 or baseline Bortezomib therapy should be interrupted at the onset of any Grade 3 hematologic or non-hematological toxicities, excluding neuropathy. Hematological toxicity during a cycle: Grade 3 or higher neutropenia, or a platelet count not at or above 25 x 10^9/L: Withhold bortezomib therapy for up to 2 weeks until the patient has an ANC at or above 0.75 x 10^9/L and a platelet count at or above 25 x 10^9/L. If, after bortezomib has been withheld, the toxicity does not resolve, discontinue bortezomib. If toxicity resolves such that the patient has an ANC at or above 0.75 x 10^9/L and a platelet count at or above 25 x 10^9/L, the bortezomib dose should be reduced by 1 dose level (from 1.3 mg/m2 to 1 mg/m2, or from 1 mg/m2 to 0.7 mg/m2) Grade 3 or higher non-hematological toxicities: Withhold bortezomib therapy until symptoms of the toxicity have resolved to Grade 2 or better. Then, bortezomib may be reinitiated with one dose level reduction (from 1.3 mg/m2 to 1 mg/m2, or from 1 mg/m2 to 0.7 mg/m2). DOSE MODIFICATION GUIDELINES FOR RELAPSED MULTIPLE MYELOMA AND MANTLE CELL LYMPHOMA: Bortezomib should be withheld at the onset of any grade 3 nonhematologic or grade 4 toxicities excluding neuropathy. Once the symptoms of the toxicity have been resolved, bortezomib therapy may be reinitiated at a 25% reduced dose (1.3 mg/m2 is reduced to 1 mg/m2, 1 mg/m2 is reduced to 0.7 mg/m2). Patients with preexisting severe neuropathy should be treated with bortezomib only after a careful risk/benefit assessment. DOSE MODIFICATION GUIDELINES FOR ALL PATIENTS ON BORTEZOMIB: For patients who experience bortezomib-related neuropathic pain and/or peripheral sensory neuropathy the following modifications in the dose or regimen is recommended: Grade 1 (paresthesias and/or loss of reflexes) without pain or loss of function – no action is required. Grade 1 with pain or Grade 2 (interfering with function but not with activities of daily living) – reduce the dose of bortezomib to 1 mg/m2. Grade 2 with pain or Grade 3 (interfering with activities of daily living) – withhold bortezomib therapy until toxicity resolves. Once the toxicity resolves, reinitiate therapy with a reduced dose of bortezomib at 0.7 mg/m2 and change the frequency to once a week. Grade 4 (a permanent sensory loss that interferes with function) – discontinue bortezomib. Side Effects The Most Common general weakness tiredness nausea vomiting diarrhea constipation loss of appetite stomach pain headache pain, redness, bruising, bleeding, or hardness at the injection site difficulty falling asleep or staying asleep More Common weakness in the arms or legs, changes in the sense of touch, or pain, burning, numbness, or tingling in the hands, arms, legs, or feet sudden shooting or stabbing pain, constant aching or burning pain, or muscle weakness shortness of breath, fast heartbeat, headache, dizziness, pale skin, confusion, or tiredness swelling of the feet, ankles, or lower legs hives, rash, itching hoarseness, difficulty swallowing or breathing, or swelling of the face, throat, tongue, lips, eyes, or hands fever, sore throat, chills, cough or other signs of infection unusual bruising or bleeding black and tarry stools, red blood in stools, bloody vomit, or vomiting material that looks like coffee grounds slurred speech or inability to speak or understand speech, confusion, paralysis (loss of ability to move a part of the body), vision changes, or loss of vision, balance, coordination, memory or consciousness fainting, blurred vision, dizziness, nausea, or muscle cramps chest pressure or pain, fast heartbeat, swelling of the ankles or feet, or shortness of breath cough, shortness of breath, wheezing, or difficulty breathing headache, confusion, seizures, tiredness, or vision loss or changes pinpoint-sized purple dots under the skin, fever, tiredness, dizziness, shortness of breath, bruising, confusion, sleepiness, seizures, decreased urination, blood in the urine, or swelling in legs fever, headache, chills, nausea, pain, itching or tingling followed by a rash in the same area with skin blisters that are itchy or painful nausea, extreme tiredness, unusual bleeding or bruising, lack of energy, loss of appetite, pain in the upper right part of the stomach, yellowing of the skin or eyes, or flu-like symptoms. Rare changes in blood pressure confusion cough dizziness, lightheadedness, or fainting inability to urinate low blood pressure (e.g., dizziness or fainting) shortness of breath skin rash chest pain irregular or rapid heartbeat seizures severe abdominal pain signs of anemia (low red blood cells; e.g., dizziness, pale skin, unusual tiredness or weakness, shortness of breath) signs of bleeding (e.g., bloody nose, blood in urine, coughing blood, bleeding gums, cuts that don’t stop bleeding) signs of breathing problems (e.g., shortness of breath, troubled breathing, wheezing, or tightness in chest, fast or irregular breathing) signs of depression (e.g., poor concentration, changes in weight, changes in sleep, decreased interest in activities, thoughts of suicide) signs of heart problems (e.g., fast, irregular heartbeat or pulse, chest pain, difficulty breathing) signs of infection (symptoms may include fever or chills, severe diarrhea, shortness of breath, prolonged dizziness, headache, stiff neck, weight loss, or listlessness) symptoms of dehydration (excessive thirst, weakness, decreased urine production, dark urine) symptoms of liver damage (yellowing of the skin or eyes, abdominal pain, nausea, dark urine, pale stool, itching, or fluid buildup in the abdomen) symptoms of shingles (e.g., headache; sensitivity to light; aching joints followed by an itchy, tingling, or painful skin rash) signs of a severe skin reaction such as blistering, peeling, a rash covering a large area of the body, a rash that spreads quickly, or a rash combined with fever or discomfort symptoms of a severe allergic reaction (e.g., hives; difficulty breathing; swelling of the face, mouth, tongue, or throat)symptoms of a stroke (sudden numbness or weakness, especially on one side of the body; sudden confusion, difficulty speaking or understanding speech; sudden problems with coordination or balance; sudden vision problems in one or both eyes; sudden, severe headache with no other cause) symptoms of gastrointestinal (stomach or intestine) bleeding (such as blood in the stools; black, tarry stools; coughing or vomiting up of blood or material that looks like coffee grounds; abdominal pain; shortness of breath; and weakness or fatigue) Interaction DRUG INTERACTION Abametapir The serum concentration of Bortezomib can be increased when it is combined with Abametapir. Abatacept The metabolism of Bortezomib can be increased when combined with Abatacept. Abciximab The risk or severity of bleeding can be increased when Abciximab is combined with Bortezomib. Abemaciclib The serum concentration of Abemaciclib can be increased when it is combined with Bortezomib. Abiraterone The serum concentration of Bortezomib can be increased when it is combined with Abiraterone. Abrocitinib The serum concentration of Bortezomib can be increased when it is combined with Abrocitinib. Acalabrutinib The metabolism of Bortezomib can be decreased when combined with Acalabrutinib. Acebutolol The metabolism of Bortezomib can be decreased when combined with Acebutolol. Acenocoumarol The metabolism of Acenocoumarol can be decreased when combined with Bortezomib. Acetaminophen The metabolism of Bortezomib can be increased when combined with Acetaminophen. Acetazolamide The metabolism of Bortezomib can be decreased when combined with Acetazolamide. Acetohexamide The metabolism of Acetohexamide can be decreased when combined with Bortezomib. Acetyl sulfisoxazole The metabolism of Bortezomib can be decreased when combined with Acetyl sulfisoxazole. Acetyldigitoxin Acetyldigitoxin may decrease the cardiotoxic activities of Bortezomib. Acetylsalicylic acid The risk or severity of bleeding can be increased when Acetylsalicylic acid is combined with Bortezomib. Acrivastine The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Acrivastine. Acyclovir The metabolism of Acyclovir can be decreased when combined with Bortezomib. Adalimumab The metabolism of Bortezomib can be increased when combined with Adalimumab. Adenosine The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Adenosine. Adenovirus type The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Bortezomib. Afatinib The serum concentration of Bortezomib can be increased when it is combined with Afatinib. Agomelatine The metabolism of Agomelatine can be decreased when combined with Bortezomib. Ajmaline The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Ajmaline. Albendazole The metabolism of Bortezomib can be increased when combined with Albendazole. Aldesleukin The metabolism of Bortezomib can be decreased when combined with Aldesleukin. Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Bortezomib. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Bortezomib. Alfuzosin The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Alfuzosin. Alimemazine The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Alimemazine. Allogeneic The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Bortezomib. Allopurinol The risk or severity of adverse effects can be increased when Allopurinol is combined with Bortezomib. Almotriptan The metabolism of Almotriptan can be decreased when combined with Bortezomib. Alogliptin The metabolism of Alogliptin can be decreased when combined with Bortezomib. Alosetron The metabolism of Bortezomib can be decreased when combined with Alosetron. Alpelisib The serum concentration of Bortezomib can be decreased when it is combined with Alpelisib. Alteplase The risk or severity of bleeding can be increased when Alteplase is combined with Bortezomib. Altretamine The risk or severity of adverse effects can be increased when Bortezomib is combined with Altretamine. Amantadine The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Amantadine. Ambrisentan The serum concentration of Bortezomib can be increased when it is combined with Ambrisentan. Amifampridine The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Amifampridine. Aminoglutethimide The metabolism of Bortezomib can be increased when combined with Aminoglutethimide. Aminophenazone The metabolism of Aminophenazone can be decreased when combined with Bortezomib. Aminophylline The metabolism of Aminophylline can be decreased when combined with Bortezomib. Amiodarone The metabolism of Bortezomib can be decreased when combined with Amiodarone. Amisulpride The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Amisulpride. Amitriptyline The metabolism of Amitriptyline can be decreased when combined with Bortezomib. Amobarbital The metabolism of Bortezomib can be increased when combined with Amobarbital. Amodiaquine The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Amodiaquine. Amoxapine The metabolism of Amoxapine can be decreased when combined with Bortezomib. Amphetamine The metabolism of Bortezomib can be decreased when combined with Amphetamine. Amprenavir The metabolism of Bortezomib can be decreased when combined with Amprenavir. Amsacrine The risk or severity of adverse effects can be increased when Bortezomib is combined with Amsacrine. Anagrelide The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Anagrelide. Anakinra The metabolism of Bortezomib can be increased when combined with Anakinra. Anastrozole The risk or severity of cardiotoxicity can be increased when Bortezomib is combined with Anastrozole. Ancrod The risk or severity of bleeding can be increased when Ancrod is combined with Bortezomib. Anifrolumab The risk or severity of adverse effects can be increased when Bortezomib is combined with Anifrolumab. Anistreplase The risk or severity of bleeding can be increased when Anistreplase is combined with Bortezomib. Antazoline The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Antazoline. Anthrax immune globulin The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Bortezomib. Anthrax vaccine The risk or severity of infection can be increased when Anthrax vaccine is combined with Bortezomib. immunoglobulin (horse) The risk or severity of adverse effects can be increased when Bortezomib is combined with Antilymphocyte immunoglobulin (horse). Antipyrine The metabolism of Antipyrine can be decreased when combined with Bortezomib. Antithrombin Alfa The risk or severity of bleeding can be increased when Antithrombin Alfa is combined with Bortezomib. Antithrombin III human The risk or severity of bleeding can be increased when Antithrombin III human is combined with Bortezomib. Antithymocyte The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Bortezomib. Apalutamide The metabolism of Bortezomib can be increased when combined with Apalutamide. Apixaban The metabolism of Apixaban can be decreased when combined with Bortezomib. Apomorphine The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Apomorphine. Apremilast The metabolism of Bortezomib can be increased when combined with Apremilast. Aprepitant The metabolism of Bortezomib can be decreased when combined with Aprepitant. Ardeparin The risk or severity of bleeding can be increased when Ardeparin is combined with Bortezomib. Arformoterol The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Arformoterol. Argatroban The risk or severity of bleeding can be increased when Argatroban is combined with Bortezomib. Aripiprazole The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Aripiprazole. Aripiprazole lauroxil The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Aripiprazole lauroxil. Armodafinil The metabolism of Bortezomib can be increased when combined with Armodafinil. Arsenic trioxide The serum concentration of Bortezomib can be increased when it is combined with Arsenic trioxide. Artemether The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Artemether. Artenimol The metabolism of Bortezomib can be decreased when combined with Artenimol. Articaine The risk or severity of methemoglobinemia can be increased when Bortezomib is combined with Articaine. Asciminib The serum concentration of Bortezomib can be increased when it is combined with Asciminib. Ascorbic acid The therapeutic efficacy of Bortezomib can be decreased when used in combination with Ascorbic acid. Asenapine The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Asenapine. Astemizole The metabolism of Bortezomib can be decreased when combined with Astemizole. COVID-19 Vaccine The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Bortezomib. Asunaprevir The metabolism of Bortezomib can be decreased when combined with Asunaprevir. Atazanavir The metabolism of Bortezomib can be decreased when combined with Atazanavir. Atenolol The metabolism of Atenolol can be decreased when combined with Bortezomib. Atomoxetine The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Atomoxetine. Atovaquone The metabolism of Bortezomib can be decreased when combined with Atovaquone. Atropine The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Atropine. Avacopan The metabolism of Bortezomib can be decreased when combined with Avacopan. Avanafil The serum concentration of Avanafil can be increased when it is combined with Bortezomib. Avapritinib The metabolism of Bortezomib can be decreased when combined with Avapritinib. Avatrombopag The serum concentration of Bortezomib can be increased when it is combined with Avatrombopag. Axitinib The metabolism of Axitinib can be decreased when combined with Bortezomib. Azacitidine The risk or severity of adverse effects can be increased when Bortezomib is combined with Azacitidine. Azatadine The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Azatadine. Azathioprine The risk or severity of adverse effects can be increased when Bortezomib is combined with Azathioprine. Baricitinib The risk or severity of adverse effects can be increased when Bortezomib is combined with Baricitinib. Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Bortezomib. BCG vaccine The risk or severity of infection can be increased when BCG vaccine is combined with Bortezomib. Beclomethasone dipropionate The metabolism of Bortezomib can be increased when combined with Beclomethasone dipropionate. Bedaquiline The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Bedaquiline. Belantamab mafodotin The serum concentration of Bortezomib can be increased when it is combined with Belantamab mafodotin. Belatacept The risk or severity of adverse effects can be increased when Bortezomib is combined with Belatacept. Belimumab The risk or severity of adverse effects can be increased when Bortezomib is combined with Belimumab. Belinostat The risk or severity of adverse effects can be increased when Bortezomib is combined with Belinostat. Belumosudil The serum concentration of Bortezomib can be increased when it is combined with Belumosudil. Belzutifan The serum concentration of Bortezomib can be decreased when it is combined with Belzutifan. Bemiparin The risk or severity of bleeding can be increased when Bemiparin is combined with Bortezomib. Bendamustine The risk or severity of adverse effects can be increased when Bortezomib is combined with Bendamustine. Bendroflumethiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Bendroflumethiazide is combined with Bortezomib. Benzatropine The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Benzatropine. Benzocaine The risk or severity of methemoglobinemia can be increased when Bortezomib is combined with Benzocaine. Benzthiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Benzthiazide is combined with Bortezomib. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Bortezomib is combined with Benzyl alcohol. Bepridil The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Bepridil. Berotralstat The serum concentration of Bortezomib can be increased when it is combined with Berotralstat. Betamethasone The metabolism of Bortezomib can be increased when combined with Betamethasone. Betamethasone phosphate The metabolism of Bortezomib can be increased when combined with Betamethasone phosphate. Betaxolol The metabolism of Betaxolol can be decreased when combined with Bortezomib. Betrixaban The serum concentration of Bortezomib can be increased when it is combined with Betrixaban. Bevacizumab The risk or severity of cardiotoxicity can be increased when Bevacizumab is combined with Bortezomib. Bexarotene The metabolism of Bortezomib can be increased when combined with Bexarotene. Bicalutamide The metabolism of Bortezomib can be decreased when combined with Bicalutamide. Bifonazole The metabolism of Bortezomib can be decreased when combined with Bifonazole. Bilastine The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Bilastine. Bimekizumab The metabolism of Bortezomib can be increased when combined with Bimekizumab. Binimetinib The metabolism of Binimetinib can be decreased when combined with Bortezomib. Biperiden The metabolism of Bortezomib can be decreased when combined with Biperiden. Bisoprolol The serum concentration of Bortezomib can be increased when it is combined with Bisoprolol. Bivalirudin The risk or severity of bleeding can be increased when Bivalirudin is combined with Bortezomib. Bleomycin The risk or severity of adverse effects can be increased when Bortezomib is combined with Bleomycin. Blinatumomab The risk or severity of adverse effects can be increased when Bortezomib is combined with Blinatumomab. Boceprevir The metabolism of Bortezomib can be decreased when combined with Boceprevir. Bordetella The therapeutic efficacy of Bordetella pertussis toxoid antigen (formaldehyde, glutaraldehyde inactivated) can be decreased when used in combination with Bortezomib. Bosentan The metabolism of Bortezomib can be increased when combined with Bosentan. Bosutinib The metabolism of Bortezomib can be decreased when combined with Bosutinib. Brentuximab vedotin The metabolism of Bortezomib can be decreased when combined with Brentuximab vedotin. Bretylium The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Bretylium. Brexpiprazole The metabolism of Brexpiprazole can be decreased when combined with Bortezomib. Brivaracetam The metabolism of Brivaracetam can be decreased when combined with Bortezomib. Brodalumab The risk or severity of adverse effects can be increased when Bortezomib is combined with Brodalumab. Bromazepam The metabolism of Bromazepam can be decreased when combined with Bortezomib. Bromotheophylline The metabolism of Bromotheophylline can be decreased when combined with Bortezomib. Brompheniramine The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Brompheniramine. Buclizine The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Buclizine. Budesonide The metabolism of Bortezomib can be increased when combined with Budesonide. Bupivacaine The risk or severity of methemoglobinemia can be increased when Bortezomib is combined with Bupivacaine. Buprenorphine The metabolism of Bortezomib can be decreased when combined with Buprenorphine. Bupropion The metabolism of Bortezomib can be decreased when combined with Bupropion. Buserelin The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Buserelin. Buspirone The metabolism of Buspirone can be decreased when combined with Bortezomib. Busulfan The risk or severity of adverse effects can be increased when Bortezomib is combined with Busulfan. Butacaine The risk or severity of methemoglobinemia can be increased when Bortezomib is combined with Butacaine. Butalbital The metabolism of Bortezomib can be increased when combined with Butalbital. Butamben The risk or severity of methemoglobinemia can be increased when Bortezomib is combined with Butamben. Butriptyline The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Butriptyline. Cabazitaxel The risk or severity of adverse effects can be increased when Bortezomib is combined with Cabazitaxel. Cabergoline The serum concentration of Cabergoline can be increased when it is combined with Bortezomib. Cabozantinib The metabolism of Cabozantinib can be decreased when combined with Bortezomib. Caffeine The metabolism of Bortezomib can be decreased when combined with Caffeine. Calcitriol The metabolism of Bortezomib can be increased when combined with Calcitriol. Calcium ascorbate The therapeutic efficacy of Bortezomib can be decreased when used in combination with Calcium ascorbate. Canagliflozin The serum concentration of Bortezomib can be increased when it is combined with Canagliflozin. Canakinumab The metabolism of Bortezomib can be increased when combined with Canakinumab. Candesartan cilexetil The metabolism of Candesartan cilexetil can be decreased when combined with Bortezomib. Candicidin The metabolism of Bortezomib can be decreased when combined with Candicidin. Cangrelor The risk or severity of bleeding can be increased when Cangrelor is combined with Bortezomib. Cannabidiol The metabolism of Bortezomib can be decreased when combined with Cannabidiol. Capecitabine The risk or severity of adverse effects can be increased when Bortezomib is combined with Capecitabine. Caplacizumab The risk or severity of bleeding can be increased when Caplacizumab is combined with Bortezomib. Capmatinib The serum concentration of Bortezomib can be increased when it is combined with Capmatinib. Capsaicin The risk or severity of methemoglobinemia can be increased when Bortezomib is combined with Capsaicin. Carbamazepine The metabolism of Bortezomib can be increased when combined with Carbamazepine. Carbinoxamine The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Carbinoxamine. Carboplatin The risk or severity of adverse effects can be increased when Bortezomib is combined with Carboplatin. Carfilzomib The serum concentration of Bortezomib can be increased when it is combined with Carfilzomib. Carisoprodol The metabolism of Carisoprodol can be decreased when combined with Bortezomib. Carmustine The risk or severity of adverse effects can be increased when Bortezomib is combined with Carmustine. Carvedilol The serum concentration of Bortezomib can be increased when it is combined with Carvedilol. Cefradine The metabolism of Bortezomib can be increased when combined with Cefradine. Celecoxib The metabolism of Bortezomib can be decreased when combined with Celecoxib. Celiprolol The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Celiprolol. Cenobamate The serum concentration of Bortezomib can be decreased when it is combined with Cenobamate. Cephalexin The metabolism of Bortezomib can be decreased when combined with Cephalexin. Ceritinib The metabolism of Bortezomib can be decreased when combined with Ceritinib. Cerivastatin The metabolism of Bortezomib can be increased when combined with Cerivastatin. Certolizumab pegol The metabolism of Bortezomib can be increased when combined with Certolizumab pegol. Cetirizine The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Cetirizine. Cevimeline The metabolism of Bortezomib can be decreased when combined with Cevimeline. Chlorambucil The risk or severity of adverse effects can be increased when Bortezomib is combined with Chlorambucil. Chloramphenicol The metabolism of Bortezomib can be decreased when combined with Chloramphenicol. Cilostazol The serum concentration of Cilostazol can be increased when it is combined with Bortezomib. Cimetidine The metabolism of Bortezomib can be decreased when combined with Cimetidine. Cinacalcet The metabolism of Bortezomib can be decreased when combined with Cinacalcet. Cinchocaine The risk or severity of methemoglobinemia can be increased when Bortezomib is combined with Cinchocaine. Cinnarizine The metabolism of Cinnarizine can be decreased when combined with Bortezomib. Cinoxacin The metabolism of Bortezomib can be decreased when combined with Cinoxacin. Ciprofloxacin The metabolism of Bortezomib can be decreased when combined with Ciprofloxacin. Cisapride The metabolism of Bortezomib can be decreased when combined with Cisapride. Cisplatin The risk or severity of adverse effects can be increased when Bortezomib is combined with Cisplatin. Citalopram The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Citalopram. Cladribine The risk or severity of adverse effects can be increased when Bortezomib is combined with Cladribine. Clarithromycin The metabolism of Bortezomib can be decreased when combined with Clarithromycin. Clemastine The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Clemastine. Clevidipine The metabolism of Bortezomib can be increased when combined with Clevidipine. Clobazam The metabolism of Bortezomib can be decreased when combined with Clobazam. Clobetasol propionate The metabolism of Bortezomib can be increased when combined with Clobetasol propionate. Clofarabine The risk or severity of adverse effects can be increased when Bortezomib is combined with Clofarabine. Clofazimine The serum concentration of Bortezomib can be increased when it is combined with Clofazimine. Clofibrate The metabolism of Bortezomib can be increased when combined with Clofibrate. Clomifene The serum concentration of Bortezomib can be increased when it is combined with Clomifene. Clomipramine The metabolism of Clomipramine can be decreased when combined with Bortezomib. Clonidine The metabolism of Clonidine can be decreased when combined with Bortezomib. Clopidogrel The metabolism of Clopidogrel can be decreased when combined with Bortezomib. Clostridium tetani The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Bortezomib. Clozapine The risk or severity of neutropenia can be increased when Bortezomib is combined with Clozapine. Cobicistat The metabolism of Bortezomib can be decreased when combined with Cobicistat. Cobimetinib The metabolism of Bortezomib can be decreased when combined with Cobimetinib. Cocaine The risk or severity of methemoglobinemia can be increased when Bortezomib is combined with Cocaine. Codeine The metabolism of Codeine can be decreased when combined with Bortezomib. Colchicine The serum concentration of Bortezomib can be increased when it is combined with Colchicine. Conivaptan The metabolism of Bortezomib can be decreased when combined with Conivaptan. Conjugated estrogens The metabolism of Conjugated estrogens can be decreased when combined with Bortezomib. Copanlisib The serum concentration of Copanlisib can be increased when it is combined with Bortezomib. Corticotropin The metabolism of Bortezomib can be increased when combined with Corticotropin. Cortisone acetate The metabolism of Bortezomib can be increased when combined with Cortisone acetate. Corynebacterium The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Bortezomib. Crizotinib The metabolism of Bortezomib can be decreased when combined with Crizotinib. Curcumin The metabolism of Bortezomib can be decreased when combined with Curcumin. Cyanocobalamin The therapeutic efficacy of Cyanocobalamin can be decreased when used in combination with Bortezomib. Cyclizine The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Cyclizine. Cyclobenzaprine The metabolism of Cyclobenzaprine can be decreased when combined with Bortezomib. Cyclopenthiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclopenthiazide is combined with Bortezomib. Cyclophosphamide The metabolism of Bortezomib can be increased when combined with Cyclophosphamide. Cyclosporine Bortezomib may increase the immunosuppressive activities of Cyclosporine. Cyclothiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Cyclothiazide is combined with Bortezomib. Cyproheptadine The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Cyproheptadine. Cyproterone acetate The metabolism of Bortezomib can be increased when combined with Cyproterone acetate. Cytarabine The risk or severity of adverse effects can be increased when Bortezomib is combined with Cytarabine. Dabigatran The risk or severity of bleeding can be increased when Dabigatran is combined with Bortezomib. Dabigatran etexilate The serum concentration of Bortezomib can be increased when it is combined with Dabigatran etexilate. Dabrafenib The serum concentration of Bortezomib can be decreased when it is combined with Dabrafenib. Dacarbazine The risk or severity of adverse effects can be increased when Bortezomib is combined with Dacarbazine. Daclatasvir The serum concentration of Bortezomib can be increased when it is combined with Daclatasvir. Dacomitinib The serum concentration of Bortezomib can be increased when it is combined with Dacomitinib. Dactinomycin The risk or severity of adverse effects can be increased when Bortezomib is combined with Dactinomycin. Dalfopristin The metabolism of Bortezomib can be decreased when combined with Dalfopristin. Dalteparin The risk or severity of bleeding can be increased when Dalteparin is combined with Bortezomib. Danaparoid The risk or severity of bleeding can be increased when Danaparoid is combined with Bortezomib. Danazol The metabolism of Bortezomib can be decreased when combined with Danazol. Dapagliflozin The metabolism of Bortezomib can be decreased when combined with Dapagliflozin. Dapsone The metabolism of Dapsone can be decreased when combined with Bortezomib. Daptomycin The serum concentration of Bortezomib can be increased when it is combined with Daptomycin. Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Bortezomib. Darifenacin The metabolism of Bortezomib can be decreased when combined with Darifenacin. Darolutamide The serum concentration of Bortezomib can be increased when it is combined with Darolutamide. Darunavir The serum concentration of Bortezomib can be increased when it is combined with Darunavir. Dasabuvir The serum concentration of Bortezomib can be increased when it is combined with Dasabuvir. Dasatinib The metabolism of Bortezomib can be decreased when combined with Dasatinib. Daunorubicin The metabolism of Bortezomib can be decreased when combined with Daunorubicin. Debrisoquine The metabolism of Debrisoquine can be decreased when combined with Bortezomib. Decitabine The risk or severity of adverse effects can be increased when Bortezomib is combined with Decitabine. Deferasirox The serum concentration of Bortezomib can be increased when it is combined with Deferasirox. Defibrotide The risk or severity of bleeding can be increased when Defibrotide is combined with Bortezomib. Deflazacort The metabolism of Bortezomib can be increased when combined with Deflazacort. Degarelix The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Degarelix. Delafloxacin The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Delafloxacin. Delamanid Bortezomib may increase the QTc-prolonging activities of Delamanid. Delavirdine The metabolism of Bortezomib can be decreased when combined with Delavirdine. Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Bortezomib. Desflurane The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Desflurane. Desipramine The metabolism of Bortezomib can be decreased when combined with Desipramine. Desirudin The risk or severity of bleeding can be increased when Desirudin is combined with Bortezomib. Deslanoside Deslanoside may decrease the cardiotoxic activities of Bortezomib. Desloratadine The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Desloratadine. Desogestrel The metabolism of Desogestrel can be decreased when combined with Bortezomib. Desoximetasone The risk or severity of adverse effects can be increased when Bortezomib is combined with Desoximetasone. Desvenlafaxine The metabolism of Bortezomib can be decreased when combined with Desvenlafaxine. Deucravacitinib The risk or severity of adverse effects can be increased when Bortezomib is combined with Deucravacitinib. Deutetrabenazine The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Deutetrabenazine. Dexlansoprazole The metabolism of Dexlansoprazole can be decreased when combined with Bortezomib. Dexmedetomidine The metabolism of Bortezomib can be decreased when combined with Dexmedetomidine. Dexrazoxane The risk or severity of adverse effects can be increased when Bortezomib is combined with Dexrazoxane. Dextran The risk or severity of bleeding can be increased when Dextran is combined with Bortezomib. Dextroamphetamine The metabolism of Dextroamphetamine can be decreased when combined with Bortezomib. Dextromethorphan The metabolism of Dextromethorphan can be decreased when combined with Bortezomib. Dextropropoxyphene The metabolism of Bortezomib can be decreased when combined with Dextropropoxyphene. Diacerein The metabolism of Bortezomib can be decreased when combined with Diacerein. Diazepam The metabolism of Diazepam can be decreased when combined with Bortezomib. Diclofenac The metabolism of Diclofenac can be decreased when combined with Bortezomib. Dicloxacillin The metabolism of Bortezomib can be increased when combined with Dicloxacillin. Dicoumarol The risk or severity of bleeding can be increased when Dicoumarol is combined with Bortezomib. Diethylstilbestrol The metabolism of Bortezomib can be decreased when combined with Diethylstilbestrol. Difluocortolone The metabolism of Bortezomib can be increased when combined with Difluocortolone. Digitoxin The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Digitoxin. Digoxin The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Digoxin. Dihydralazine The metabolism of Bortezomib can be decreased when combined with Dihydralazine. Dihydrocodeine The metabolism of Dihydrocodeine can be decreased when combined with Bortezomib. Dihydroergocornine The metabolism of Bortezomib can be decreased when combined with Dihydroergocornine. Dihydroergocristine The metabolism of Bortezomib can be decreased when combined with Dihydroergocristine. Dihydroergotamine The metabolism of Bortezomib can be decreased when combined with Dihydroergotamine. Diltiazem The metabolism of Bortezomib can be decreased when combined with Diltiazem. Dimenhydrinate The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Dimenhydrinate. Dimethyl fumarate The risk or severity of adverse effects can be increased when Bortezomib is combined with Dimethyl fumarate. Dimethyl sulfoxide The metabolism of Bortezomib can be decreased when combined with Dimethyl sulfoxide. Dinutuximab The risk or severity of adverse effects can be increased when Bortezomib is combined with Dinutuximab. Diosmin The serum concentration of Bortezomib can be increased when it is combined with Diosmin. Diphenhydramine The risk or severity of methemoglobinemia can be increased when Bortezomib is combined with Diphenhydramine. Dipyridamole The risk or severity of bleeding can be increased when Dipyridamole is combined with Bortezomib. Diroximel fumarate The risk or severity of adverse effects can be increased when Bortezomib is combined with Diroximel fumarate. Disopyramide The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Disopyramide. Disulfiram The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Disulfiram. Docetaxel The metabolism of Bortezomib can be decreased when combined with Docetaxel. Doconexent The metabolism of Bortezomib can be decreased when combined with Doconexent. Dofetilide The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Dofetilide. Dolasetron The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Dolasetron. Dolutegravir The serum concentration of Bortezomib can be increased when it is combined with Dolutegravir. Domperidone The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Domperidone. Donepezil The metabolism of Donepezil can be decreased when combined with Bortezomib. Dosulepin The metabolism of Bortezomib can be decreased when combined with Dosulepin. Doxazosin The metabolism of Bortezomib can be decreased when combined with Doxazosin. Doxepin The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Doxepin. Doxorubicin The metabolism of Bortezomib can be decreased when combined with Doxorubicin. Doxylamine The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Doxylamine. Dronabinol The metabolism of Bortezomib can be decreased when combined with Dronabinol. Dronedarone The metabolism of Bortezomib can be decreased when combined with Dronedarone. Droperidol The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Droperidol. Drospirenone The metabolism of Bortezomib can be decreased when combined with Drospirenone. Drotrecogin alfa The risk or severity of bleeding can be increased when Drotrecogin alfa is combined with Bortezomib. Duloxetine The metabolism of Bortezomib can be decreased when combined with Duloxetine. Duvelisib The metabolism of Bortezomib can be decreased when combined with Duvelisib. Dyclonine The risk or severity of methemoglobinemia can be increased when Bortezomib is combined with Dyclonine. Ebastine The metabolism of Bortezomib can be decreased when combined with Ebastine. Ebola Zaire The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Bortezomib. Echinacea The metabolism of Bortezomib can be increased when combined with Echinacea. Econazole The metabolism of Bortezomib can be decreased when combined with Econazole. Eculizumab The risk or severity of adverse effects can be increased when Bortezomib is combined with Eculizumab. Edetic acid The risk or severity of bleeding can be increased when Edetic acid is combined with Bortezomib. Edoxaban The serum concentration of Bortezomib can be increased when it is combined with Edoxaban. Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Bortezomib. Efavirenz The metabolism of Bortezomib can be decreased when combined with Efavirenz. Elagolix The serum concentration of Bortezomib can be increased when it is combined with Elagolix. Elbasvir The serum concentration of Bortezomib can be increased when it is combined with Elbasvir. Eletriptan The metabolism of Eletriptan can be decreased when combined with Bortezomib. Elexacaftor The metabolism of Bortezomib can be decreased when combined with Elexacaftor. Eliglustat The metabolism of Bortezomib can be decreased when combined with Eliglustat. Eltrombopag The metabolism of Eltrombopag can be decreased when combined with Bortezomib. Elvitegravir The metabolism of Bortezomib can be decreased when combined with Elvitegravir. Emapalumab The metabolism of Bortezomib can be increased when combined with Emapalumab. Emedastine The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Emedastine. Enasidenib The serum concentration of Bortezomib can be increased when it is combined with Enasidenib. Encainide The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Encainide. Encorafenib The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Encorafenib. Enfortumab vedotin The serum concentration of Bortezomib can be increased when it is combined with Enfortumab vedotin. Enoxacin The metabolism of Bortezomib can be decreased when combined with Enoxacin. Enoxaparin The risk or severity of bleeding can be increased when Enoxaparin is combined with Bortezomib. Entacapone The metabolism of Bortezomib can be decreased when combined with Entacapone. Entecavir The metabolism of Entecavir can be decreased when combined with Bortezomib. Entrectinib The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Entrectinib. Enzalutamide The metabolism of Bortezomib can be increased when combined with Enzalutamide. Epinastine The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Epinastine. Epinephrine The metabolism of Bortezomib can be decreased when combined with Epinephrine. Epirubicin The risk or severity of adverse effects can be increased when Bortezomib is combined with Epirubicin. Epoprostenol The risk or severity of bleeding can be increased when Epoprostenol is combined with Bortezomib. Eptifibatide The risk or severity of bleeding can be increased when Eptifibatide is combined with Bortezomib. Erdafitinib The serum concentration of Bortezomib can be increased when it is combined with Erdafitinib. Ergotamine The metabolism of Bortezomib can be decreased when combined with Ergotamine. Eribulin The risk or severity of adverse effects can be increased when Bortezomib is combined with Eribulin. Erlotinib The metabolism of Bortezomib can be decreased when combined with Erlotinib. Ertugliflozin The serum concentration of Bortezomib can be increased when it is combined with Ertugliflozin. Erythromycin The serum concentration of Bortezomib can be increased when it is combined with Erythromycin. Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Bortezomib. Escitalopram The serum concentration of Bortezomib can be increased when it is combined with Escitalopram. Esketamine The metabolism of Bortezomib can be increased when combined with Esketamine. Esmolol The risk or severity of QTc prolongation can be increased when Esmolol is combined with Bortezomib. Esomeprazole The metabolism of Esomeprazole can be decreased when combined with Bortezomib. Estetrol The metabolism of Bortezomib can be decreased when combined with Estetrol. Estradiol The metabolism of Estradiol can be decreased when combined with Bortezomib. Estradiol acetate The metabolism of Bortezomib can be increased when combined with Estradiol acetate. Estradiol benzoate The metabolism of Bortezomib can be increased when combined with Estradiol benzoate. Estradiol cypionate The metabolism of Bortezomib can be increased when combined with Estradiol cypionate. Estradiol dienanthate The metabolism of Bortezomib can be increased when combined with Estradiol dienanthate. Estradiol valerate The metabolism of Bortezomib can be increased when combined with Estradiol valerate. Estramustine The risk or severity of adverse effects can be increased when Bortezomib is combined with Estramustine. Estrone sulfate The metabolism of Bortezomib can be decreased when combined with Estrone sulfate. Etanercept The metabolism of Bortezomib can be increased when combined with Etanercept. Ethambutol The metabolism of Bortezomib can be decreased when combined with Ethambutol. Ethanol The metabolism of Bortezomib can be increased when combined with Ethanol. Ethinylestradiol The metabolism of Ethinylestradiol can be decreased when combined with Bortezomib. Ethosuximide The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Ethosuximide. Ethyl chloride The risk or severity of methemoglobinemia can be increased when Bortezomib is combined with Ethyl chloride. Etidocaine The risk or severity of methemoglobinemia can be increased when Bortezomib is combined with Etidocaine. Etodolac The metabolism of Etodolac can be decreased when combined with Bortezomib. Etoposide The risk or severity of adverse effects can be increased when Bortezomib is combined with Etoposide. Etoricoxib The metabolism of Bortezomib can be decreased when combined with Etoricoxib. Etravirine The metabolism of Bortezomib can be increased when combined with Etravirine. Everolimus The serum concentration of Bortezomib can be increased when it is combined with Everolimus. Ezogabine The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Ezogabine. Famotidine The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Famotidine. Favipiravir The serum concentration of Bortezomib can be increased when it is combined with Favipiravir. Fedratinib The serum concentration of Bortezomib can be increased when it is combined with Fedratinib. Felbamate The metabolism of Bortezomib can be increased when combined with Felbamate. Felodipine The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Felodipine. Fenfluramine The metabolism of Bortezomib can be decreased when combined with Fenfluramine. Fenofibrate The metabolism of Bortezomib can be decreased when combined with Fenofibrate. Fesoterodine The metabolism of Fesoterodine can be decreased when combined with Bortezomib. Fexinidazole The risk or severity of adverse effects can be increased when Bortezomib is combined with Fexinidazole. Fexofenadine The serum concentration of Bortezomib can be increased when it is combined with Fexofenadine. Filgotinib The serum concentration of Bortezomib can be increased when it is combined with Filgotinib. Fingolimod Bortezomib may increase the immunosuppressive activities of Fingolimod. Flecainide The metabolism of Flecainide can be decreased when combined with Bortezomib. Flibanserin The serum concentration of Bortezomib can be increased when it is combined with Flibanserin. Floxuridine The risk or severity of adverse effects can be increased when Bortezomib is combined with Floxuridine. Flucloxacillin The metabolism of Bortezomib can be increased when combined with Flucloxacillin. Fluconazole The serum concentration of Bortezomib can be increased when it is combined with Fluconazole. Flucytosine The risk or severity of adverse effects can be increased when Bortezomib is combined with Flucytosine. Fludarabine The risk or severity of adverse effects can be increased when Bortezomib is combined with Fludarabine. Fludrocortisone The risk or severity of adverse effects can be increased when Bortezomib is combined with Fludrocortisone. Fluindione The risk or severity of bleeding can be increased when Fluindione is combined with Bortezomib. Flunarizine The metabolism of Flunarizine can be decreased when combined with Bortezomib. Flunisolide The metabolism of Bortezomib can be increased when combined with Flunisolide. Flunitrazepam The metabolism of Flunitrazepam can be decreased when combined with Bortezomib. Fluocinolone acetonide The metabolism of Bortezomib can be increased when combined with Fluocinolone acetonide. Fluocinonide The metabolism of Bortezomib can be increased when combined with Fluocinonide. Fluocortolone The metabolism of Bortezomib can be increased when combined with Fluocortolone. Fluorometholone The risk or severity of adverse effects can be increased when Bortezomib is combined with Fluorometholone. Fluorouracil The risk or severity of adverse effects can be increased when Bortezomib is combined with Fluorouracil. Fluoxetine The serum concentration of Bortezomib can be increased when it is combined with Fluoxetine. Flupentixol The risk or severity of myelosuppression can be increased when Flupentixol is combined with Bortezomib. Fluphenazine The metabolism of Bortezomib can be decreased when combined with Fluphenazine. Fluprednisolone The risk or severity of adverse effects can be increased when Bortezomib is combined with Fluprednisolone. Flurbiprofen The metabolism of Flurbiprofen can be decreased when combined with Bortezomib. Fluspirilene The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Fluspirilene. Flutamide The metabolism of Flutamide can be decreased when combined with Bortezomib. Fluticasone The metabolism of Bortezomib can be increased when combined with Fluticasone. Fluticasone furoate The metabolism of Bortezomib can be increased when combined with Fluticasone furoate. Fluticasone propionate The metabolism of Bortezomib can be decreased when combined with Fluticasone propionate. Fluvastatin The metabolism of Bortezomib can be decreased when combined with Fluvastatin. Fluvoxamine The metabolism of Bortezomib can be decreased when combined with Fluvoxamine. Fondaparinux The risk or severity of bleeding can be increased when Fondaparinux is combined with Bortezomib. Formestane The metabolism of Bortezomib can be increased when combined with Formestane. Formoterol The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Formoterol. Fosamprenavir The metabolism of Bortezomib can be decreased when combined with Fosamprenavir. Fosaprepitant The metabolism of Bortezomib can be increased when combined with Fosaprepitant. Foscarnet The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Foscarnet. Fosnetupitant The metabolism of Bortezomib can be decreased when combined with Fosnetupitant. Fosphenytoin The metabolism of Bortezomib can be increased when combined with Fosphenytoin. Fostamatinib The metabolism of Bortezomib can be decreased when combined with Fostamatinib. Fostemsavir The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Fostemsavir. Frovatriptan The metabolism of Frovatriptan can be decreased when combined with Bortezomib. Fusidic acid The metabolism of Bortezomib can be decreased when combined with Fusidic acid. Futibatinib The serum concentration of Bortezomib can be increased when it is combined with Futibatinib. Gadobenic acid The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Gadobenic acid. Galantamine The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Galantamine. Gallium nitrate The risk or severity of adverse effects can be increased when Bortezomib is combined with Gallium nitrate. Gatifloxacin The metabolism of Bortezomib can be decreased when combined with Gatifloxacin. Gefitinib The metabolism of Bortezomib can be decreased when combined with Gefitinib. Gemcitabine The risk or severity of adverse effects can be increased when Bortezomib is combined with Gemcitabine. Gemfibrozil The metabolism of Bortezomib can be decreased when combined with Gemfibrozil. Gemifloxacin The metabolism of Bortezomib can be decreased when combined with Gemifloxacin. Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Bortezomib. Gilteritinib The metabolism of Bortezomib can be decreased when combined with Gilteritinib. Ginkgo biloba The metabolism of Bortezomib can be decreased when combined with Ginkgo biloba. Givosiran The serum concentration of Bortezomib can be increased when it is combined with Givosiran. Glasdegib The serum concentration of Bortezomib can be increased when it is combined with Glasdegib. Glatiramer The risk or severity of adverse effects can be increased when Bortezomib is combined with Glatiramer. Glecaprevir The serum concentration of Bortezomib can be increased when it is combined with Glecaprevir. Gliclazide The metabolism of Gliclazide can be decreased when combined with Bortezomib. Glimepiride The metabolism of Glimepiride can be decreased when combined with Bortezomib. Glipizide The metabolism of Glipizide can be decreased when combined with Bortezomib. Gliquidone The metabolism of Gliquidone can be decreased when combined with Bortezomib. Glyburide The metabolism of Bortezomib can be decreased when combined with Glyburide. Irbesartan The metabolism of Bortezomib can be decreased when combined with Irbesartan. Irinotecan The risk or severity of adverse effects can be increased when Bortezomib is combined with Irinotecan. Isavuconazole The serum concentration of Bortezomib can be increased when it is combined with Isavuconazole. Isavuconazonium The serum concentration of Bortezomib can be increased when it is combined with Isavuconazonium. Isoflurane The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Isoflurane. Isoniazid The metabolism of Bortezomib can be decreased when combined with Isoniazid. Isradipine The metabolism of Bortezomib can be decreased when combined with Isradipine. Istradefylline The serum concentration of Bortezomib can be increased when it is combined with Istradefylline. Itraconazole The metabolism of Bortezomib can be decreased when combined with Itraconazole. Ivabradine The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Ivabradine. Ivacaftor The serum concentration of Bortezomib can be increased when it is combined with Ivacaftor. Ivosidenib The metabolism of Bortezomib can be increased when combined with Ivosidenib. Ixabepilone The serum concentration of Bortezomib can be increased when it is combined with Ixabepilone. Ixekizumab The risk or severity of adverse effects can be increased when Bortezomib is combined with Ixekizumab. Janssen COVID-19 Vaccine The therapeutic efficacy of Janssen COVID-19 Vaccine can be decreased when used in combination with Bortezomib. Japanese encephalitis The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Bortezomib. Ketamine The metabolism of Ketamine can be decreased when combined with Bortezomib. Ketazolam The metabolism of Bortezomib can be decreased when combined with Ketazolam. Ketoconazole The metabolism of Bortezomib can be decreased when combined with Ketoconazole. Ketorolac The metabolism of Ketorolac can be decreased when combined with Bortezomib. Labetalol The metabolism of Labetalol can be decreased when combined with Bortezomib. Lacidipine The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Lacidipine. Lacosamide The metabolism of Bortezomib can be decreased when combined with Lacosamide. Lansoprazole The metabolism of Lansoprazole can be decreased when combined with Bortezomib. Lapatinib The serum concentration of Bortezomib can be increased when it is combined with Lapatinib. Larotrectinib The serum concentration of Bortezomib can be increased when it is combined with Larotrectinib. Lasmiditan The serum concentration of Bortezomib can be increased when it is combined with Lasmiditan. Ledipasvir The serum concentration of Bortezomib can be increased when it is combined with Ledipasvir. Lefamulin Lefamulin may increase the QTc-prolonging activities of Bortezomib. Leflunomide The risk or severity of adverse effects can be increased when Bortezomib is combined with Leflunomide. Lemborexant The serum concentration of Bortezomib can be increased when it is combined with Lemborexant. Lenalidomide The risk or severity of adverse effects can be increased when Bortezomib is combined with Lenalidomide. Lenvatinib The serum concentration of Bortezomib can be increased when it is combined with Lenvatinib. Lepirudin The risk or severity of bleeding can be increased when Lepirudin is combined with Bortezomib. Lesinurad The metabolism of Bortezomib can be increased when combined with Lesinurad. Letermovir The metabolism of Bortezomib can be decreased when combined with Letermovir. Leuprolide The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Leuprolide. Levacetylmethadol The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Levacetylmethadol. Levobetaxolol The metabolism of Levobetaxolol can be decreased when combined with Bortezomib. Levobupivacaine The risk or severity of methemoglobinemia can be increased when Bortezomib is combined with Levobupivacaine. Levocabastine The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Levocabastine. Levocetirizine The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Levocetirizine. Levofloxacin The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Levofloxacin. Levoketoconazole The metabolism of Bortezomib can be decreased when combined with Levoketoconazole. Levomenthol The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Levomenthol. Levomilnacipran The metabolism of Levomilnacipran can be decreased when combined with Bortezomib. Levosimendan The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Levosimendan. Levothyroxine The serum concentration of Bortezomib can be decreased when it is combined with Levothyroxine. Lidocaine The risk or severity of methemoglobinemia can be increased when Bortezomib is combined with Lidocaine. Lidoflazine The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Lidoflazine. Linagliptin The serum concentration of Bortezomib can be increased when it is combined with Linagliptin. Linezolid The risk or severity of adverse effects can be increased when Bortezomib is combined with Linezolid. Lipegfilgrastim Bortezomib may increase the myelosuppressive activities of Lipegfilgrastim. Lisdexamfetamine The metabolism of Bortezomib can be decreased when combined with Lisdexamfetamine. Lisuride The metabolism of Lisuride can be decreased when combined with Bortezomib. Lofexidine The metabolism of Lofexidine can be decreased when combined with Bortezomib. Lomefloxacin The metabolism of Lomefloxacin can be decreased when combined with Bortezomib. Lomitapide The serum concentration of Bortezomib can be increased when it is combined with Lomitapide. Lomustine The risk or severity of adverse effects can be increased when Bortezomib is combined with Lomustine. Lonafarnib The metabolism of Bortezomib can be decreased when combined with Lonafarnib. Lonapegsomatropin The metabolism of Bortezomib can be increased when combined with Lonapegsomatropin. Loncastuximab tesirine The serum concentration of Bortezomib can be increased when it is combined with Loncastuximab tesirine. Loperamide The serum concentration of Bortezomib can be increased when it is combined with Loperamide. Lopinavir The serum concentration of Bortezomib can be increased when it is combined with Lopinavir. Lorcaserin The metabolism of Bortezomib can be decreased when combined with Lorcaserin. Lorlatinib The serum concentration of Bortezomib can be decreased when it is combined with Lorlatinib. Lornoxicam The metabolism of Lornoxicam can be decreased when combined with Bortezomib. Lorpiprazole The metabolism of Lorpiprazole can be decreased when combined with Bortezomib. Losartan The metabolism of Bortezomib can be decreased when combined with Losartan. Lovastatin The metabolism of Bortezomib can be decreased when combined with Lovastatin. Loxapine The serum concentration of Bortezomib can be increased when it is combined with Loxapine. Lumacaftor The metabolism of Bortezomib can be increased when combined with Lumacaftor. Lumefantrine The metabolism of Bortezomib can be decreased when combined with Lumefantrine. Lumiracoxib The metabolism of Lumiracoxib can be decreased when combined with Bortezomib. Lurasidone The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Lurasidone. Lusutrombopag The serum concentration of Bortezomib can be increased when it is combined with Lusutrombopag. Lynestrenol The metabolism of Lynestrenol can be decreased when combined with Bortezomib. Macimorelin The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Macimorelin. Magnesium The serum concentration of Magnesium can be decreased when it is combined with Bortezomib. Manidipine The metabolism of Bortezomib can be decreased when combined with Manidipine. Mannitol The serum concentration of Bortezomib can be increased when it is combined with Mannitol. Maprotiline The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Maprotiline. Maribavir The serum concentration of Bortezomib can be increased when it is combined with Maribavir. Mavacamten The serum concentration of Mavacamten can be increased when it is combined with Bortezomib. Measles virus vaccine The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Bortezomib. Mechlorethamine The risk or severity of adverse effects can be increased when Bortezomib is combined with Mechlorethamine. Meclizine The metabolism of Meclizine can be decreased when combined with Bortezomib. Medroxyprogesterone acetate The metabolism of Bortezomib can be increased when combined with Medroxyprogesterone acetate. Mefenamic acid The metabolism of Mefenamic acid can be decreased when combined with Bortezomib. Mefloquine The serum concentration of Bortezomib can be increased when it is combined with Mefloquine. Melatonin The metabolism of Melatonin can be decreased when combined with Bortezomib. Meloxicam The risk or severity of methemoglobinemia can be increased when Bortezomib is combined with Meloxicam. Melphalan The risk or severity of adverse effects can be increased when Bortezomib is combined with Melphalan. Meningococcal The therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Bortezomib. Meperidine The metabolism of Bortezomib can be decreased when combined with Meperidine. Mephenytoin The metabolism of Mephenytoin can be decreased when combined with Bortezomib. Mepivacaine The risk or severity of methemoglobinemia can be increased when Bortezomib is combined with Mepivacaine. Mepolizumab The risk or severity of adverse effects can be increased when Bortezomib is combined with Mepolizumab. Meprednisone The metabolism of Bortezomib can be increased when combined with Meprednisone. Mepyramine The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Mepyramine. Mercaptopurine The risk or severity of adverse effects can be increased when Bortezomib is combined with Mercaptopurine. Mesoridazine The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Mesoridazine. Mestranol The metabolism of Mestranol can be decreased when combined with Bortezomib. Metamfetamine The metabolism of Metamfetamine can be decreased when combined with Bortezomib. Methadone The metabolism of Bortezomib can be decreased when combined with Methadone. Methimazole The metabolism of Bortezomib can be decreased when combined with Methimazole. Methotrexate The risk or severity of adverse effects can be increased when Bortezomib is combined with Methotrexate. Methotrimeprazine The metabolism of Bortezomib can be decreased when combined with Methotrimeprazine. Methoxsalen The metabolism of Bortezomib can be decreased when combined with Methoxsalen. Methoxy polyethylene The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Bortezomib. Methoxyflurane The metabolism of Methoxyflurane can be decreased when combined with Bortezomib. Methsuximide The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Methsuximide. Methylene blue The serum concentration of Bortezomib can be increased when it is combined with Methylene blue. Methylergometrine The metabolism of Bortezomib can be decreased when combined with Methylergometrine. Methylphenobarbital The metabolism of Bortezomib can be increased when combined with Methylphenobarbital. Methylprednisolone The metabolism of Bortezomib can be increased when combined with Methylprednisolone. Methylprednisone The metabolism of Bortezomib can be decreased when combined with Methylprednisone. Methysergide The metabolism of Bortezomib can be decreased when combined with Methysergide. Metoclopramide The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Metoclopramide. Metoprolol The metabolism of Bortezomib can be decreased when combined with Metoprolol. Metreleptin The metabolism of Bortezomib can be increased when combined with Metreleptin. Metronidazole The metabolism of Bortezomib can be decreased when combined with Metronidazole. Metyrapone The metabolism of Bortezomib can be increased when combined with Metyrapone. Mexiletine The metabolism of Bortezomib can be decreased when combined with Mexiletine. Mianserin The metabolism of Mianserin can be decreased when combined with Bortezomib. Miconazole The metabolism of Bortezomib can be decreased when combined with Miconazole. Midazolam The metabolism of Bortezomib can be decreased when combined with Midazolam. Midostaurin The metabolism of Bortezomib can be increased when combined with Midostaurin. Mifepristone The serum concentration of Bortezomib can be decreased when it is combined with Mifepristone. Milnacipran The metabolism of Bortezomib can be decreased when combined with Milnacipran. Minaprine The metabolism of Minaprine can be decreased when combined with Bortezomib. Miocamycin The metabolism of Bortezomib can be decreased when combined with Miocamycin. Mirabegron The serum concentration of Bortezomib can be increased when it is combined with Mirabegron. Mirtazapine The metabolism of Bortezomib can be decreased when combined with Mirtazapine. Mitapivat The metabolism of Bortezomib can be increased when combined with Mitapivat. Mitomycin The risk or severity of adverse effects can be increased when Bortezomib is combined with Mitomycin. Mitotane The metabolism of Bortezomib can be increased when combined with Mitotane. Mitoxantrone The risk or severity of adverse effects can be increased when Bortezomib is combined with Mitoxantrone. Mizolastine The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Mizolastine. Mobocertinib The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Mobocertinib. Moclobemide The metabolism of Moclobemide can be decreased when combined with Bortezomib. Modafinil The metabolism of Bortezomib can be increased when combined with Modafinil. Moderna COVID-19 Vaccine The therapeutic efficacy of Moderna COVID-19 Vaccine can be decreased when used in combination with Bortezomib. Modified vaccinia ankara The therapeutic efficacy of Modified vaccinia ankara can be decreased when used in combination with Bortezomib. Moexipril The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Moexipril. Mometasone furoate The metabolism of Bortezomib can be increased when combined with Mometasone furoate. Monomethyl fumarate The risk or severity of adverse effects can be increased when Bortezomib is combined with Monomethyl fumarate. Montelukast The metabolism of Montelukast can be decreased when combined with Bortezomib. Moricizine The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Moricizine. Morphine The serum concentration of Bortezomib can be increased when it is combined with Morphine. Mosunetuzumab The metabolism of Bortezomib can be decreased when combined with Mosunetuzumab. Moxifloxacin The metabolism of Bortezomib can be decreased when combined with Moxifloxacin. Mumps virus strain The therapeutic efficacy of Mumps virus strain B level jeryl lynn live antigen can be decreased when used in combination with Bortezomib. Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Bortezomib. Mycophenolate mofetil The risk or severity of adverse effects can be increased when Bortezomib is combined with Mycophenolate mofetil. Mycophenolic acid The risk or severity of adverse effects can be increased when Bortezomib is combined with Mycophenolic acid. Nabilone The metabolism of Nabilone can be decreased when combined with Bortezomib. Nabumetone The metabolism of Nabumetone can be decreased when combined with Bortezomib. Nadolol The metabolism of Nadolol can be decreased when combined with Bortezomib. Nadroparin The risk or severity of bleeding can be increased when Nadroparin is combined with Bortezomib. Nafcillin The metabolism of Bortezomib can be increased when combined with Nafcillin. Nalidixic acid The metabolism of Bortezomib can be decreased when combined with Nalidixic acid. Naloxone The metabolism of Bortezomib can be decreased when combined with Naloxone. Naproxen The metabolism of Naproxen can be decreased when combined with Bortezomib. Natalizumab The risk or severity of adverse effects can be increased when Bortezomib is combined with Natalizumab. Nateglinide The metabolism of Nateglinide can be decreased when combined with Bortezomib. Nebivolol The metabolism of Nebivolol can be decreased when combined with Bortezomib. Nefazodone The metabolism of Bortezomib can be decreased when combined with Nefazodone. Nelarabine The risk or severity of adverse effects can be increased when Bortezomib is combined with Nelarabine. Nelfinavir The metabolism of Bortezomib can be decreased when combined with Nelfinavir. Neratinib The serum concentration of Bortezomib can be increased when it is combined with Neratinib. Netupitant The serum concentration of Bortezomib can be increased when it is combined with Netupitant. Nevirapine The metabolism of Bortezomib can be decreased when combined with Nevirapine. Niacin The metabolism of Bortezomib can be decreased when combined with Niacin. Niacinamide ascorbate The therapeutic efficacy of Bortezomib can be decreased when used in combination with Niacinamide ascorbate. Nicardipine The metabolism of Bortezomib can be decreased when combined with Nicardipine. Nicergoline The metabolism of Nicergoline can be decreased when combined with Bortezomib. Niclosamide The metabolism of Bortezomib can be decreased when combined with Niclosamide. Nifedipine The metabolism of Nifedipine can be decreased when combined with Bortezomib. Nilotinib The metabolism of Bortezomib can be decreased when combined with Nilotinib. Nilutamide The metabolism of Nilutamide can be decreased when combined with Bortezomib. Nilvadipine The metabolism of Bortezomib can be decreased when combined with Nilvadipine. Nimesulide The risk or severity of bleeding can be increased when Nimesulide is combined with Bortezomib. Nimodipine The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Nimodipine. Nintedanib The metabolism of Bortezomib can be decreased when combined with Nintedanib. Nitrendipine The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Nitrendipine. Norethisterone The metabolism of Bortezomib can be decreased when combined with Norethisterone. Norfloxacin The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Norfloxacin. Norgestimate The serum concentration of Bortezomib can be increased when it is combined with Norgestimate. Nortriptyline The metabolism of Nortriptyline can be decreased when combined with Bortezomib. Noscapine The metabolism of Bortezomib can be decreased when combined with Noscapine. Nuvaxovid The therapeutic efficacy of Nuvaxovid can be decreased when used in combination with Bortezomib. Obeticholic acid The metabolism of Bortezomib can be decreased when combined with Obeticholic acid. Obinutuzumab The risk or severity of adverse effects can be increased when Bortezomib is combined with Obinutuzumab. Ocrelizumab Ocrelizumab may increase the immunosuppressive activities of Bortezomib. Octreotide The serum concentration of Bortezomib can be increased when it is combined with Octreotide. Ofatumumab The risk or severity of adverse effects can be increased when Bortezomib is combined with Ofatumumab. Ofloxacin The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Ofloxacin. Olanzapine The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Olanzapine. Olaparib The metabolism of Bortezomib can be decreased when combined with Olaparib. Oliceridine The metabolism of Oliceridine can be decreased when combined with Bortezomib. Olodaterol The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Olodaterol. Omadacycline The serum concentration of Bortezomib can be increased when it is combined with Omadacycline. Ombitasvir The serum concentration of Bortezomib can be increased when it is combined with Ombitasvir. Omeprazole The metabolism of Bortezomib can be increased when combined with Omeprazole. Ondansetron The metabolism of Ondansetron can be decreased when combined with Bortezomib. Opium The metabolism of Opium can be decreased when combined with Bortezomib. Oritavancin The metabolism of Bortezomib can be increased when combined with Oritavancin. Orphenadrine The metabolism of Bortezomib can be decreased when combined with Orphenadrine. Osilodrostat The metabolism of Bortezomib can be decreased when combined with Osilodrostat. Osimertinib The serum concentration of Bortezomib can be decreased when it is combined with Osimertinib. Ospemifene The metabolism of Bortezomib can be decreased when combined with Ospemifene. Ouabain Ouabain may decrease the cardiotoxic activities of Bortezomib. Oxaliplatin The risk or severity of adverse effects can be increased when Bortezomib is combined with Oxaliplatin. Oxamniquine The metabolism of Bortezomib can be decreased when combined with Oxamniquine. Oxandrolone The metabolism of Bortezomib can be decreased when combined with Oxandrolone. Oxatomide The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Oxatomide. Oxcarbazepine The metabolism of Bortezomib can be increased when combined with Oxcarbazepine. Oxetacaine The risk or severity of methemoglobinemia can be increased when Bortezomib is combined with Oxetacaine. Oxprenolol The metabolism of Bortezomib can be decreased when combined with Oxprenolol. Oxtriphylline The metabolism of Oxtriphylline can be decreased when combined with Bortezomib Oxytocin The risk or severity of QTc prolongation can be increased when Oxytocin is combined with Bortezomib. Ozanimod The risk or severity of adverse effects can be increased when Bortezomib is combined with Ozanimod. Paclitaxel The metabolism of Bortezomib can be increased when combined with Paclitaxel. Pacritinib The serum concentration of Bortezomib can be increased when it is combined with Pacritinib. Palbociclib The serum concentration of Bortezomib can be increased when it is combined with Palbociclib. Palifermin The therapeutic efficacy of Palifermin can be decreased when used in combination with Bortezomib. Paliperidone The serum concentration of Bortezomib can be increased when it is combined with Paliperidone. Palonosetron The metabolism of Palonosetron can be decreased when combined with Bortezomib. Panobinostat The metabolism of Bortezomib can be decreased when combined with Panobinostat. Pantoprazole The metabolism of Pantoprazole can be decreased when combined with Bortezomib. Papaverine The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Papaverine. Paramethadione The metabolism of Paramethadione can be decreased when combined with Bortezomib. Parecoxib The metabolism of Parecoxib can be decreased when combined with Bortezomib. Paritaprevir The serum concentration of Bortezomib can be increased when it is combined with Paritaprevir. Parnaparin The risk or severity of bleeding can be increased when Parnaparin is combined with Bortezomib. Paroxetine The metabolism of Bortezomib can be decreased when combined with Paroxetine. Pasireotide The metabolism of Bortezomib can be decreased when combined with Pasireotide. Pazopanib The metabolism of Bortezomib can be decreased when combined with Pazopanib. Pefloxacin The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Pefloxacin. Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Bortezomib. Pegcetacoplan The risk or severity of adverse effects can be increased when Bortezomib is combined with Pegcetacoplan. Peginesatide The risk or severity of Thrombosis can be increased when Peginesatide is combined with Bortezomib. Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Bortezomib. Peginterferon alfa-2b The serum concentration of Bortezomib can be increased when it is combined with Peginterferon alfa-2b. Peginterferon beta-1a The risk or severity of adverse effects can be increased when Bortezomib is combined with Peginterferon beta-1a. Pemetrexed The risk or severity of adverse effects can be increased when Bortezomib is combined with Pemetrexed. Penbutolol The metabolism of Penbutolol can be decreased when combined with Bortezomib. Penciclovir The metabolism of Penciclovir can be decreased when combined with Bortezomib. Penicillamine The risk or severity of adverse effects can be increased when Bortezomib is combined with Penicillamine. Pentamidine The metabolism of Pentamidine can be decreased when combined with Bortezomib. Pentobarbital The metabolism of Bortezomib can be increased when combined with Pentobarbital. Pentosan polysulfate The risk or severity of bleeding can be increased when Pentosan polysulfate is combined with Bortezomib. Pentostatin The risk or severity of adverse effects can be increased when Bortezomib is combined with Pentostatin. Pentoxifylline The metabolism of Pentoxifylline can be decreased when combined with Bortezomib. Perampanel The metabolism of Bortezomib can be increased when combined with Perampanel. Perflutren The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Perflutren. Perhexiline The metabolism of Bortezomib can be decreased when combined with Perhexiline. Perphenazine The metabolism of Bortezomib can be decreased when combined with Perphenazine. Pertussis vaccine The therapeutic efficacy of Pertussis vaccine can be decreased when used in combination with Bortezomib. Pertuzumab The risk or severity of cardiotoxicity can be increased when Bortezomib is combined with Pertuzumab. Pexidartinib Bortezomib may increase the hepatotoxic activities of Pexidartinib. Phenformin The metabolism of Phenformin can be decreased when combined with Bortezomib. Phenindione The risk or severity of bleeding can be increased when Phenindione is combined with Bortezomib. Pheniramine The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Pheniramine. Phenobarbital The metabolism of Bortezomib can be increased when combined with Phenobarbital. Phenol The risk or severity of methemoglobinemia can be increased when Bortezomib is combined with Phenol. Phenprocoumon The risk or severity of bleeding can be increased when Phenprocoumon is combined with Bortezomib. Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Bortezomib. Phenylbutazone The metabolism of Bortezomib can be increased when combined with Phenylbutazone. Phenylbutyric acid The metabolism of Bortezomib can be decreased when combined with Phenylbutyric acid. Phenylephrine The metabolism of Bortezomib can be increased when combined with Phenylephrine. Phenytoin The metabolism of Bortezomib can be increased when combined with Phenytoin. Pibrentasvir The serum concentration of Bortezomib can be increased when it is combined with Pibrentasvir. Pimavanserin The metabolism of Bortezomib can be decreased when combined with Pimavanserin. Pimecrolimus The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Bortezomib. Pimozide The metabolism of Pimozide can be decreased when combined with Bortezomib. Pinaverium The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Pinaverium. Pindolol The metabolism of Bortezomib can be decreased when combined with Pindolol. Piperaquine The metabolism of Bortezomib can be decreased when combined with Piperaquine. Piperazine The metabolism of Piperazine can be decreased when combined with Bortezomib. Pipotiazine The metabolism of Bortezomib can be decreased when combined with Pipotiazine. Pirfenidone The risk or severity of adverse effects can be increased when Bortezomib is combined with Pirfenidone. Piroxicam The metabolism of Piroxicam can be decreased when combined with Bortezomib. Pitavastatin The metabolism of Pitavastatin can be decreased when combined with Bortezomib. Pitolisant The serum concentration of Bortezomib can be decreased when it is combined with Pitolisant. Polythiazide The risk or severity of neutropenia and thrombocytopenia can be increased when Polythiazide is combined with Bortezomib. Pomalidomide The risk or severity of adverse effects can be increased when Bortezomib is combined with Pomalidomide. Ponatinib The serum concentration of Bortezomib can be increased when it is combined with Ponatinib. Ponesimod The risk or severity of bradycardia can be increased when Ponesimod is combined with Bortezomib. Posaconazole The metabolism of Bortezomib can be decreased when combined with Posaconazole. Practolol The metabolism of Practolol can be decreased when combined with Bortezomib. Pralatrexate The risk or severity of adverse effects can be increased when Bortezomib is combined with Pralatrexate. Pralsetinib The serum concentration of Bortezomib can be increased when it is combined with Pralsetinib. Pramocaine The risk or severity of methemoglobinemia can be increased when Bortezomib is combined with Pramocaine. Prasugrel The risk or severity of bleeding can be increased when Prasugrel is combined with Bortezomib. Pravastatin The serum concentration of Bortezomib can be increased when it is combined with Pravastatin. Praziquantel The metabolism of Praziquantel can be decreased when combined with Bortezomib. Prednisolone The metabolism of Bortezomib can be increased when combined with Prednisolone. Prednisolone acetate The metabolism of Bortezomib can be increased when combined with Prednisolone acetate. Prednisolone phosphate The serum concentration of Bortezomib can be decreased when it is combined with Prednisolone phosphate. Prednisone The risk or severity of adverse effects can be increased when Bortezomib is combined with Prednisone. Prednisone acetate The metabolism of Bortezomib can be increased when combined with Prednisone acetate. Pregabalin The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Pregabalin. Prenylamine The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Prenylamine. Pretomanid The metabolism of Bortezomib can be decreased when combined with Pretomanid. Prilocaine The risk or severity of methemoglobinemia can be increased when Bortezomib is combined with Prilocaine. Primaquine The metabolism of Bortezomib can be decreased when combined with Primaquine. Primidone The metabolism of Bortezomib can be increased when combined with Primidone. Probenecid The metabolism of Bortezomib can be increased when combined with Probenecid. Probucol The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Probucol. Procainamide The metabolism of Procainamide can be decreased when combined with Bortezomib. Procaine The risk or severity of methemoglobinemia can be increased when Bortezomib is combined with Procaine. Procarbazine The risk or severity of adverse effects can be increased when Bortezomib is combined with Procarbazine. Ribociclib The metabolism of Bortezomib can be decreased when combined with Ribociclib. Rifabutin The metabolism of Bortezomib can be increased when combined with Rifabutin. Rifampicin The metabolism of Bortezomib can be increased when combined with Rifampicin. Rifamycin The metabolism of Bortezomib can be increased when combined with Rifamycin. Rifapentine The metabolism of Bortezomib can be increased when combined with Rifapentine. Rilonacept The metabolism of Bortezomib can be increased when combined with Rilonacept. Rilpivirine The metabolism of Bortezomib can be decreased when combined with Rilpivirine. Riluzole The metabolism of Riluzole can be decreased when combined with Bortezomib. Rimegepant The serum concentration of Bortezomib can be increased when it is combined with Rimegepant. Riociguat The serum concentration of Bortezomib can be increased when it is combined with Riociguat. Ripretinib The serum concentration of Bortezomib can be increased when it is combined with Ripretinib. Risankizumab The risk or severity of adverse effects can be increased when Bortezomib is combined with Risankizumab. Risperidone The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Risperidone. Ritonavir The serum concentration of Bortezomib can be increased when it is combined with Ritonavir. Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Bortezomib. Rivaroxaban The serum concentration of Bortezomib can be increased when it is combined with Rivaroxaban. Rofecoxib The metabolism of Bortezomib can be increased when combined with Rofecoxib. Roflumilast Roflumilast may increase the immunosuppressive activities of Bortezomib. Rolapitant The metabolism of Bortezomib can be decreased when combined with Rolapitant. Romidepsin The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Romidepsin. Ropeginterferon alfa- The risk or severity of adverse effects can be increased when Bortezomib is combined with Ropeginterferon alfa-2b. Ropivacaine The risk or severity of methemoglobinemia can be increased when Bortezomib is combined with Ropivacaine. Rosiglitazone The metabolism of Rosiglitazone can be decreased when combined with Bortezomib. Rosoxacin The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Rosoxacin. Rosuvastatin The metabolism of Bortezomib can be decreased when combined with Rosuvastatin. Rotavirus vaccine The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Bortezomib. Rotigotine The metabolism of Bortezomib can be decreased when combined with Rotigotine. Roxithromycin The metabolism of Bortezomib can be decreased when combined with Roxithromycin. Rubella virus vaccine The risk or severity of infection can be increased when Rubella virus vaccine is combined with Bortezomib. Rucaparib The metabolism of Bortezomib can be decreased when combined with Rucaparib. Rufinamide The metabolism of Bortezomib can be increased when combined with Rufinamide. Rupatadine The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Rupatadine. Ruxolitinib The risk or severity of adverse effects can be increased when Bortezomib is combined with Ruxolitinib. Salbutamol The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Salbutamol. Salicylic acid The metabolism of Salicylic acid can be decreased when combined with Bortezomib. Salmeterol The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Salmeterol. Sapropterin The serum concentration of Bortezomib can be increased when it is combined with Sapropterin. Saquinavir The metabolism of Bortezomib can be decreased when combined with Saquinavir. Sarecycline The serum concentration of Bortezomib can be increased when it is combined with Sarecycline. Sarilumab The metabolism of Bortezomib can be increased when combined with Sarilumab. Satralizumab The serum concentration of Bortezomib can be decreased when it is combined with Satralizumab. Secobarbital The metabolism of Bortezomib can be increased when combined with Secobarbital. Secukinumab The metabolism of Bortezomib can be increased when combined with Secukinumab. Selegiline The metabolism of Selegiline can be decreased when combined with Bortezomib. Selexipag The serum concentration of Bortezomib can be increased when it is combined with Selexipag. Selumetinib The metabolism of Selumetinib can be decreased when combined with Bortezomib. Sertindole The metabolism of Sertindole can be decreased when combined with Bortezomib. Sertraline The metabolism of Sertraline can be decreased when combined with Bortezomib. Sevoflurane The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Sevoflurane. Sildenafil The serum concentration of Bortezomib can be increased when it is combined with Sildenafil. Silodosin The serum concentration of Bortezomib can be increased when it is combined with Silodosin. Siltuximab The metabolism of Bortezomib can be increased when combined with Siltuximab. Simeprevir The serum concentration of Bortezomib can be increased when it is combined with Simeprevir. Simvastatin The serum concentration of Bortezomib can be increased when it is combined with Simvastatin. Siponimod The risk or severity of adverse effects can be increased when Bortezomib is combined with Siponimod. Sipuleucel-T The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Bortezomib. Sirolimus The risk or severity of adverse effects can be increased when Bortezomib is combined with Sirolimus. Sitagliptin The serum concentration of Bortezomib can be increased when it is combined with Sitagliptin. Sitaxentan The metabolism of Bortezomib can be decreased when combined with Sitaxentan. Smallpox (Vaccinia) The therapeutic efficacy of the Smallpox (Vaccinia) Vaccine, Live can be decreased when used in combination with Bortezomib. Sodium ascorbate The therapeutic efficacy of Bortezomib can be decreased when used in combination with Sodium ascorbate. Sodium citrate The risk or severity of bleeding can be increased when Sodium citrate is combined with Bortezomib. Sofosbuvir The serum concentration of Bortezomib can be increased when it is combined with Sofosbuvir. Solifenacin The risk or severity of QTc prolongation can be increased when Bortezomib is combined with Solifenacin. Pregnancy and Lactation FDA Pregnancy Category D Pregnancy No studies have been conducted to determine the effect of bortezomib on an unborn baby if the medication is used during pregnancy. Women should avoid becoming pregnant while taking bortezomib. Men and women should use effective contraception during bortezomib treatment and for the 3 months following treatment. If you become pregnant while using this medication, contact your doctor immediately. Breast-feeding It is not known if bortezomib passes into breast milk. If you are a breastfeeding mother and are taking this medication, it may affect your baby. Women should not breastfeed while taking bortezomib. How should this medicine be used? Bortezomib comes as a solution (liquid) to inject into a vein or subcutaneously (under the skin). Bortezomib is given by a doctor or nurse in a medical office or clinic. Your dosing schedule will depend on the condition that you have, the other medications you are using, and how well your body responds to treatment. Be sure to tell your doctor how you are feeling during your treatment. Your doctor may stop your treatment for a while or decrease your dose of bortezomib if you experience side effects of the medication. Ask your pharmacist or doctor for a copy of the manufacturer’s information for the patient. Other uses for this medicine This medication may be prescribed for other uses; ask your doctor or pharmacist for more information. What special precautions should I follow? Before using bortezomib, tell your doctor and healthcare provider if you are allergic to bortezomib, mannitol, any other medications, boron, or any of the ingredients in bortezomib. Ask your healthcare provider for a list of the ingredients. tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, or nutritional supplements you are taking or plan to take. Be sure to mention any of the following: clarithromycin (Biaxin, in PrevPac); certain antifungals such as itraconazole (Sporanox) or ketoconazole (Nizoral); idelalisib (Zydelig); medications to treat diabetes or high blood pressure; certain medications to treat human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) such as indinavir (Crixivan), nelfinavir (Viracept), ritonavir (Norvir), or saquinavir (Invirase); certain medications to treat seizures such as carbamazepine (Carbatrol, Tegretol), phenobarbital (Luminal, Solfoton), or phenytoin (Dilantin, Phenytek); nefazodone; ribociclib (Kisqali, Kisqali, in Femera); rifabutin (Mycobutin); or rifampin (Rifadin, Rifamate, Rimactane, others). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. Many other medications may also interact with bortezomib, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list. tell your doctor what herbal products you are taking, especially St. John’s wort. tell your doctor if you or anyone in your family has or has ever had heart disease and if you have or have ever had a herpes infection (cold sores, shingles, or genital sores); diabetes; fainting; high cholesterol (fats in the blood); low or high blood pressure; peripheral neuropathy (numbness, pain, tingling, or burning feeling in the feet or hands) or weakness or loss of feeling or reflexes in a part of your body;or kidney or liver disease. Also tell your doctor if you smoke or drink large amounts of alcohol. tell your doctor if you are pregnant or plan to become pregnant. Bortezomib may harm the fetus. Use birth control to prevent pregnancy during your treatment with bortezomib and for at least 7 months after your final dose. If you are a male with a female partner who could become pregnant, be sure to use birth control during your treatment with bortezomib and for at least 4 months after your final dose. Ask your doctor if you have questions about types of birth control that will work for you. If you or your partner become pregnant while using bortezomib or for 7 months after your final dose, call your doctor immediately. do not breastfeed during your treatment with bortezomib and for 2 months after your final dose. if you are having surgery, including dental surgery, tell the doctor or dentist that you are using bortezomib. you should know that bortezomib may make you drowsy, dizzy, or lightheaded, or cause fainting or blurred vision. Do not drive a car or operate machinery or dangerous tools until you know how this medication affects you. you should know that bortezomib may cause dizziness, lightheadedness, and fainting when you get up too quickly from a lying position. This is more common in people who have fainted in the past, people who are dehydrated, and people who are taking medications that lower blood pressure. To avoid this problem, get out of bed slowly, resting your feet on the floor for a few minutes before standing up. References https://pubchem.ncbi.nlm.nih.gov/compound/Bortezomib https://go.drugbank.com/drugs/DB00188 https://medlineplus.gov/druginfo/meds/a607007.html https://www.ncbi.nlm.nih.gov/books/NBK519559/ https://www.drugs.com/mtm/bortezomib.html https://www.medbroadcast.com/drug/getdrug/bortezomib-for-injection https://www.webmd.com/drugs/2/drug-75263/bortezomib-injection/details/list-contraindications ChEMBL http://www.ebi.ac.uk/Information/termsofuse.html https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL325041/ ChEMBL Protein Target Tree https://www.ebi.ac.uk/chembl/g/#browse/targets Comparative Toxicogenomics Database (CTD) http://ctdbase.org/about/legal.jsp https://ctdbase.org/detail.go?type=chem&acc=D000069286 Drug Gene Interaction database (DGIdb) http://www.dgidb.org/downloads https://www.dgidb.org/drugs/BORTEZOMIB DrugBank https://www.drugbank.ca/legal/terms_of_use Bortezomib https://www.drugbank.ca/drugs/DB00188 IUPHAR/BPS Guide to PHARMACOLOGY https://www.guidetopharmacology.org/about.jsp#license https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6391 Guide to Pharmacology Target Classification https://www.guidetopharmacology.org/targets.jsp Therapeutic Target Database (TTD) Bortezomib http://idrblab.net/ttd/data/drug/details/D0SH3I CAS Common Chemistry LICENSE The data from CAS Common Chemistry is provided under a CC-BY-NC 4.0 license, unless otherwise stated. https://creativecommons.org/licenses/by-nc/4.0/ Bortezomib https://commonchemistry.cas.org/detail?cas_rn=179324-69-7 ChemIDplus LICENSE https://www.nlm.nih.gov/copyright.html Bortezomib [USAN:INN:BAN] https://chem.nlm.nih.gov/chemidplus/sid/0179324697 ChemIDplus Chemical Information Classification https://chem.nlm.nih.gov/chemidplus/ DTP/NCI https://www.cancer.gov/policies/copyright-reuse Bortezomib https://dtp.cancer.gov/dtpstandard/servlet/dwindex?searchtype=NSC&outputformat=html&searchlist=681239 EPA DSSTox LICENSE https://www.epa.gov/privacy/privacy-act-laws-policies-and-resources Bortezomib https://comptox.epa.gov/dashboard/DTXSID3040980 CompTox Chemicals Dashboard Chemical Lists https://comptox.epa.gov/dashboard/chemical-lists/ FDA Global Substance Registration System (GSRS) https://www.fda.gov/about-fda/about-website/website-policies#linking BORTEZOMIB https://gsrs.ncats.nih.gov/ginas/app/beta/substances/69G8BD63PP Hazardous Substances Data Bank (HSDB) BORTEZOMIB https://pubchem.ncbi.nlm.nih.gov/source/hsdb/7666 Human Metabolome Database (HMDB) http://www.hmdb.ca/citing Bortezomib http://www.hmdb.ca/metabolites/HMDB0014334 HMDB0014334_msms_374196 https://hmdb.ca/metabolites/HMDB0014334#spectra ChEBI Bortezomib http://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:52717 ChEBI Ontology http://www.ebi.ac.uk/chebi/userManualForward.do#ChEBI%20Ontology FDA Pharm Classes https://www.fda.gov/about-fda/about-website/website-policies#linking BORTEZOMIB https://dailymed.nlm.nih.gov/dailymed/browse-drug-classes.cfm FDA Pharmacological Classification https://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/ucm162549.htm LiverTox LICENSE https://www.nlm.nih.gov/copyright.html Bortezomib https://www.ncbi.nlm.nih.gov/books/n/livertox/Bortezomib/ ClinicalTrials.gov https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use https://clinicaltrials.gov/ DailyMed LICENSE https://www.nlm.nih.gov/copyright.html BORTEZOMIB https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=BORTEZOMIB Drug Induced Liver Injury Rank (DILIrank) Dataset https://www.fda.gov/about-fda/about-website/website-policies#linking bortezomib https://www.fda.gov/science-research/liver-toxicity-knowledge-base-ltkb/drug-induced-liver-injury-rank-dilirank-dataset Nature Chemical Biology https://pubchem.ncbi.nlm.nih.gov/substance/184610884 European Medicines Agency (EMA) https://www.ema.europa.eu/en/about-us/legal-notice Velcade (EMEA/H/C/000539) https://www.ema.europa.eu/en/medicines/human/EPAR/velcade Bortezomib Hospira (EMEA/H/C/004207) https://www.ema.europa.eu/en/medicines/human/EPAR/bortezomib-hospira Bortezomib Fresenius Kabi (EMEA/H/C/005074) https://www.ema.europa.eu/en/medicines/human/EPAR/bortezomib-fresenius-kabi Bortezomib Sun (EMEA/H/C/004076) https://www.ema.europa.eu/en/medicines/human/EPAR/bortezomib-sun Bortezomib Accord (EMEA/H/C/003984) https://www.ema.europa.eu/en/medicines/human/EPAR/bortezomib-accord bortezomib (P/78/2008) https://www.ema.europa.eu/en/medicines/human/paediatric-investigation-plans/bortezomib EU Clinical Trials Register https://www.clinicaltrialsregister.eu/ European Chemicals Agency (ECHA) https://echa.europa.eu/web/guest/legal-notice [(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/96430 FDA Orange Book https://www.fda.gov/about-fda/about-website/website-policies#linking https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book NORMAN Suspect List Exchange LICENSE Data: CC-BY 4.0; Code (hosted by ECI, LCSB): Artistic-2.0 https://creativecommons.org/licenses/by/4.0/ NORMAN Suspect List Exchange Classification https://www.norman-network.com/nds/SLE/ WHO Anatomical Therapeutic Chemical (ATC) Classification https://www.whocc.no/copyright_disclaimer/ https://www.whocc.no/atc/ ATC Code https://www.whocc.no/atc_ddd_index/ National Drug Code (NDC) Directory https://www.fda.gov/about-fda/about-website/website-policies#linking BORTEZOMIB https://www.fda.gov/drugs/drug-approvals-and-databases/national-drug-code-directory MassBank of North America (MoNA) LICENSE The content of the MoNA database is licensed under CC BY 4.0. https://mona.fiehnlab.ucdavis.edu/documentation/license Bortezomib (Velcade) https://mona.fiehnlab.ucdavis.edu/spectra/browse?query=compound.metaData%3Dq%3D%27name%3D%3D%22InChIKey%22%20and%20value%3D%3D%22GXJABQQUPOEUTA-RDJZCZTQSA-N%22%27 NCI Cancer Drugs LICENSE https://www.cancer.gov/policies/copyright-reuse Bortezomib https://www.cancer.gov/about-cancer/treatment/drugs/bortezomib NIPH Clinical Trials Search of Japan https://rctportal.niph.go.jp/en/ NLM RxNorm Terminology https://www.nlm.nih.gov/research/umls/rxnorm/docs/termsofservice.html https://rxnav.nlm.nih.gov/id/rxnorm/358258 Protein Data Bank in Europe (PDBe) http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/BO2 PubChem https://pubchem.ncbi.nlm.nih.gov RCSB Protein Data Bank (RCSB PDB) https://www.rcsb.org/pages/policies https://www.rcsb.org/ Springer Nature https://pubchem.ncbi.nlm.nih.gov/substance/?source=15745&sourceid=28051279-486443100 https://pubchem.ncbi.nlm.nih.gov/substance/?source=15745&sourceid=28051279-486435622 Thieme Chemistry https://creativecommons.org/licenses/by-nc-nd/4.0/ https://pubchem.ncbi.nlm.nih.gov/substance/?source=22163&sourceid=28051279-486435622 WHO Model Lists of Essential Medicines https://www.who.int/about/who-we-are/publishing-policies/copyright Bortezomib https://list.essentialmeds.org/medicines/407 Wikidata LICENSE CCZero https://creativecommons.org/publicdomain/zero/1.0/ Bortezomib https://www.wikidata.org/wiki/Q419319 Wiley https://pubchem.ncbi.nlm.nih.gov/substance/?source=wiley&sourceid=126409 Medical Subject Headings (MeSH) https://www.nlm.nih.gov/copyright.html Bortezomib https://www.ncbi.nlm.nih.gov/mesh/2009944 MeSH Tree http://www.nlm.nih.gov/mesh/meshhome.html Antineoplastic Agents https://www.ncbi.nlm.nih.gov/mesh/68000970 KEGG LICENSE Academic users may freely use the KEGG website. Non-academic use of KEGG generally requires a commercial license https://www.kegg.jp/kegg/legal.html Therapeutic category of drugs in Japan http://www.genome.jp/kegg-bin/get_htext?br08301.keg USP drug classification http://www.genome.jp/kegg-bin/get_htext?br08302.keg Anatomical Therapeutic Chemical (ATC) classification http://www.genome.jp/kegg-bin/get_htext?br08303.keg Target-based classification of drugs http://www.genome.jp/kegg-bin/get_htext?br08310.keg Drug Groups http://www.genome.jp/kegg-bin/get_htext?br08330.keg UN Globally Harmonized System of Classification and Labelling of Chemicals (GHS) GHS Classification Tree http://www.unece.org/trans/danger/publi/ghs/ghs_welcome_e.html PATENTSCOPE (WIPO) SID 388833096 https://pubchem.ncbi.nlm.nih.gov/substance/388833096 NCBI https://www.ncbi.nlm.nih.gov/projects/linkout Show More